TY  - JOUR
  - Clarke G, O'Mahony SM, Cryan JF, Dinan TG
  - 2009
  - April
  - Human Psychopharmacology
  - Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter?
  - Published
  - WOS: 30 ()
  - 24
  - 3
  - 217
  - 223
  - Verapamil is a calcium channel blocker that also inhibits the P-glycoprotein (Pgp) membrane transporter. We have found that administration of verapamil with a recognised antidepressant improves clinical outcome in previously treatment resistant cases despite the fact that verapamil does not possess inherent antidepressant activity. In this study we examined the hypothesis that the antidepressant-like effects of verapamil are mediated through its blockade of the Pgp transporter in the blood brain barrier (BBB).
  - 10.1002/hup.1008
DA  - 2009/04
ER  - 

@article{V8985828,
   = {Clarke G,  O'Mahony SM and  Cryan JF,  Dinan TG },
   = {2009},
   = {April},
   = {Human Psychopharmacology},
   = {Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter?},
   = {Published},
   = {WOS: 30 ()},
   = {24},
   = {3},
  pages = {217--223},
   = {{Verapamil is a calcium channel blocker that also inhibits the P-glycoprotein (Pgp) membrane transporter. We have found that administration of verapamil with a recognised antidepressant improves clinical outcome in previously treatment resistant cases despite the fact that verapamil does not possess inherent antidepressant activity. In this study we examined the hypothesis that the antidepressant-like effects of verapamil are mediated through its blockade of the Pgp transporter in the blood brain barrier (BBB).}},
   = {10.1002/hup.1008},
  source = {IRIS}
}